Fine-tuning the cytotoxicity of ruthenium(<scp>ii</scp>) arene compounds to enhance selectivity against breast cancers

Pereira, Sarah A. P.; Romano-deGea, Jan; Barbosa, Ana Isabel; Costa Lima, Sofia A.; Dyson, Paul J.; Saraiva, M. Lúcia M. F. S.

doi:10.1039/d3dt02037a

Cited by 3 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary data in the literature suggest that ruthenium compounds might be good candidate agents against cancer cells. [26][27][28][29] Studies over the year suggested that ruthenium has anticancer activity against various cancer cells including breast, 30 lung, 31 prostate, and ovarian cells. 13 In this study, eight different novel ruthenium complexes were synthesized and their anticancer potential against MCF-7 cells was studied.…”

Section: Pharmacology/biologymentioning

confidence: 99%

“…Pereira et al have, in their comprehensive research with RAPTA complexes in the MCF-7 cell line, established that cationic complexes manifest enhanced cytotoxic activity when contrasted with neutral complexes. 28 In our study, apart from the cationic nature of the complex, we also elucidate the influence of solubility. Khan et al designed a series of three half-sandwich Ru(II) arene chloride complexes and conducted a cytotoxicity assessment across concentrations of 0.1, 1, 10, and 100 μM in MCF-7 cells.…”

Section: Pharmacology/biologymentioning

confidence: 99%

See 1 more Smart Citation

Ruthenium compounds: Are they the next‐era anticancer agents?

Kavukcu,

Özverel,

Kıyak

et al. 2024

Applied Organom Chemis

View full text Add to dashboard Cite

This study focuses on the cytotoxic activity of ruthenium(II) complexes, denoted as Ru1–8, which exhibit coordination with nitrogen (amine and amide), oxygen, and sulfur donor atoms, coupled with aryl and aliphatic wingtips. Specifically, the complexes were evaluated for their impact on the MCF‐7 breast cancer cell line. A systematic exploration of various parameters, including solubility, donor atom type, metal number, carbon chain length, aromatic ring presence, and molecular weight, was conducted to discern their influence on cytotoxic activity. The investigation involved assessing the cell viability across five concentrations (100, 50, 25, 10, and 5 μM) for five distinct monometallic and three bimetallic ruthenium complexes. Notably, Ru3, characterized by an extended carbon chain length (dodecyl) and favorable oil solubility facilitating cellular membrane penetration, demonstrated particularly promising results with the IC50 value of 1.03 μM. This research underscores the critical role of ligand design in shaping the cytotoxic potential of ruthenium(II) complexes and emphasizes the suitability of the Ru(II) p‐cymene complexes, as demonstrated by their robust activity against breast cancer in this specific investigation.

show abstract